Adobe (ADBE) stock faces multiple analyst downgrades before Q1 2026 earnings on March 12. Price targets slashed amid cautious Wall Street sentiment.
Browsing: Stocks
Meta (META) acquires AI agent platform Moltbook. Citizens holds $900 target as engagement surges 17% YoY. Moody’s affirms Aa3 rating on strong fundamentals.
Polymarket partners with Palantir (PLTR) and TWG AI to launch a sports integrity platform that monitors and flags suspicious trading in prediction markets.
Taiwan Semiconductor (TSM) stock climbed after reporting 30% YoY revenue growth to NT$718.91B for Jan-Feb 2026, fueled by strong AI chip demand from key clients.
Amazon (AMZN) is launching up to $42B in corporate bonds across U.S. and euro markets, marking one of the largest debt offerings ever for AI infrastructure.
US equities declined Tuesday as contradictory signals from the Iran conflict unsettled investors. Oil retreated from $120 but stays elevated above $90.
Applied Materials (AMAT) stock gained 2.16% after unveiling partnership with Micron (MU) to develop AI-focused memory products at its $5B EPIC Center facility.
Nvidia (NVDA) invests in Thinking Machines Lab and secures multi-year deal to deploy gigawatt-scale Vera Rubin systems for AI model training starting 2026.
SpaceX pursues Nasdaq listing at $1.75T valuation with fast-track Nasdaq 100 entry. Exchange proposes new rule for megacap IPOs. NYSE also competing.
Qualcomm (QCOM) slides 3% as Bank of America issues Underperform rating, citing $7-8B Apple revenue loss and weak 2% growth outlook through 2028.
Catheter Precision (VTAK) stock exploded 60% higher after announcing acquisition of remaining Fly Flyte stake and Ponderosa in $11.55M deal with Creatd.
Nvidia CEO Jensen Huang argues AI infrastructure buildout creates jobs for electricians, steelworkers & technicians—not just eliminates them.
Bitmine (BMNR) moved 9,600 ETH ($19.5M) to Coinbase Prime following last week’s record purchase of 60,976 ETH. The firm now holds over 4.5M tokens.
B.Riley starts coverage on Strategy (MSTR) with Buy rating and $175 target, citing 721,000 Bitcoin position and compressed valuation at 1.2x NAV.
MiNK Therapeutics (INKT) stock jumped 80% on a C-Further collaboration to develop PRAME-targeted iNKT cell therapy for pediatric cancer patients.